3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
2
NIH
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Carcinoma, Hepatocellular
79
Carcinoma, Renal Cell
36
Neoplasms
35
Liver Neoplasms
22
Carcinoma, Non-Small-Cell Lung
7
Carcinoma
7
Neoplasm Metastasis
6
Melanoma
5
Thyroid Neoplasms
4
Kidney Neoplasms
4
Breast Neoplasms
3
Financial Stress
2
Vaccinia
1
Stomach Neoplasms
1
Patient Preference
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms, Glandular and Epithelial
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Lymphoma
1
Lung Neoplasms
1
Liver Diseases
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Insulin-Like Growth Factor I, Resistance To
1
Hypophosphatemia
1
Hepatitis C
1
Hepatitis B
1
Glioblastoma
1
Digestive System Neoplasms
1
Interventions
nilotinib
50
Imatinib Mesylate
48
Dasatinib
25
bosutinib
18
asciminib
17
ponatinib
10
Homoharringtonine
5
Cytarabine
4
olverembatinib
3
Interferon-alpha
3
Decitabine
3
tozasertib
2
peginterferon alfa-2a
2
flumatinib
2
fludarabine phosphate
2
ON 01910
2
Mycophenolic Acid
2
Melphalan
2
Interferon alpha-2
2
Filgrastim
2
Cyclophosphamide
2
Bone Marrow Transplantation
2
BID protein, human
2
Azacitidine
2
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide
2
vosaroxin
1
troxacitabine
1
triciribine
1
terameprocol
1
sonidegib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
×
Sorafenib
×
Clear all
NCT00661180
2014-12-23
ORACLE
Bayer
Phase 2
Completed
10 enrolled